Business Description
Arovella Therapeutics Ltd
ISIN : AU0000182784
Total Employee Number:
44Description
Arovella Therapeutics Ltd is engaged in the development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer. Its invariant Natural Killer T (iNKT) cell therapy platform is being developed as a next-generation, allogeneic off-the-shelf cell therapy platform with potential applications across blood cancers, solid tumours and selected autoimmune diseases. Its product, ALA-101, is a CD19-directed CAR-iNKT cell therapy for relapsed or refractory CD19- positive blood cancers. Arovella is expanding the platform into solid tumours through ALA-105, its CLDN18.2-targeting CAR-iNKT program for gastric and pancreatic cancers, and through incorporation of IL-12-TM armouring technology designed to enhance CARiNKT cell activity and durability.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 11.5 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 12.6 | |||||
3-Year Book Growth Rate | 44.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.86 | |||||
9-Day RSI | 40.94 | |||||
14-Day RSI | 43.16 | |||||
3-1 Month Momentum % | -9.86 | |||||
6-1 Month Momentum % | -21.95 | |||||
12-1 Month Momentum % | -28.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 17.51 | |||||
Quick Ratio | 17.51 | |||||
Cash Ratio | 17.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.5 | |||||
Shareholder Yield % | -0.66 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -39.05 | |||||
ROA % | -36.5 | |||||
ROIC % | -2125.21 | |||||
3-Year ROIIC % | 455.19 | |||||
ROC (Joel Greenblatt) % | -2822.32 | |||||
ROCE % | -63.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.08 | |||||
Price-to-Tangible-Book | 6.1 | |||||
EV-to-EBIT | -5.3 | |||||
EV-to-EBITDA | -5.35 | |||||
EV-to-Forward-Revenue | 5.17 | |||||
EV-to-FCF | -8.55 | |||||
| Price-to-Net-Current-Asset-Value | 6.1 | |||||
| Price-to-Net-Cash | 6.1 | |||||
Earnings Yield (Greenblatt) % | -18.87 | |||||
FCF Yield % | -9.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arovella Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.006 | ||
| Beta | 1.5739 | ||
| 3-Year Sharpe Ratio | 0.42 | ||
| 3-Year Sortino Ratio | 0.7 | ||
| Volatility % | 32.07 | ||
| 14-Day RSI | 43.16 | ||
| 14-Day ATR (A$) | 0.002521 | ||
| 20-Day SMA (A$) | 0.0618 | ||
| 12-1 Month Momentum % | -28.09 | ||
| 52-Week Range (A$) | 0.058 - 0.125 | ||
| Shares Outstanding (Mil) | 1,208.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arovella Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arovella Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-19 | In 173 days | ||
| General meeting for 2026 | 2026-10-30 11:00 | In 62 days | ||
| Annual report for 2026 | 2026-08-21 | 0.06 (+0.00%) | ||
| Annual report for 2026 | 2026-08-20 | 0.06 (-1.56%) | ||
| Second quarter earnings results for 2026 | 2026-02-19 | 0.09 (-1.16%) | ||
| General meeting for 2025 | 2025-10-30 11:00 | 0.09 (+3.33%) | ||
| Annual report for 2025 | 2025-08-22 | 0.09 (-3.41%) | ||
| Second quarter earnings results for 2025 | 2025-02-26 | 0.20 (+0.00%) | ||
| General meeting for 2024 | 2024-11-15 11:00 | 0.21 (+0.00%) | ||
| 0.04:1 Stock Split | 2019-11-14 | 0.04 (-33.33%) |
Show
Entries
Arovella Therapeutics Ltd Frequently Asked Questions
What is Arovella Therapeutics Ltd(ASX:ALA)'s stock price today?
The current price of ASX:ALA is A$0.06. The 52 week high of ASX:ALA is A$0.13 and 52 week low is A$0.06.
When is next earnings date of Arovella Therapeutics Ltd(ASX:ALA)?
The next earnings date of Arovella Therapeutics Ltd(ASX:ALA) is 2027-02-19 Est..
Does Arovella Therapeutics Ltd(ASX:ALA) pay dividends? If so, how much?
Arovella Therapeutics Ltd(ASX:ALA) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy | 2023-10-10 |
Articles on Arovella Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers